Skip to main content

Table 1 Demographic characteristics, underlying diseases, clinical and laboratory findings, and outcomes

From: Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial

  Group p
Case (n = 30) Control (n = 30)
Age (year), mean (SD) 57.53 (18.27) 61 (15.90) 0.436
Sex, n (%)
 Female 15 (50.00%) 15 (50.00%) > 0.9
 Male 15 (50.00%) 15 (50.00%)
Hypertension, n (%) 15 (50.00%) 10 (33.33%) 0.190
Diabetes mellitus, n (%) 12 (40.00%) 11 (36.67%) 0.791
Ischemic heart disease, n (%) 4 (13.33%) 7 (23.33%) 0.506
COPD, n (%) 3 (10.00%) 3 (10.00%) > 0.9
Thyroid disease, n (%) 2 (6.67%) 3 (10.00%) > 0.9
Fever, n (%) 7 (23.33%) 19 (63.33%) 0.002
Chill, n (%) 7 (23.33%) 9 (30.00%) 0.559
Dyspnea, n (%) 25 (83.33%) 21 (70.00%) 0.222
Myalgia, n (%) 4 (13.33%) 18 (60.00%) < 0.001
Weakness, n (%) 2 (6.67%) 4 (13.33%) 0.671
Cough, n (%) 26 (86.67%) 23 (76.67%) 0.506
Sputum, n (%) 1 (3.33%) 4 (13.33%) 0.353
Headache, n (%) 3 (10.00%) 8 (26.67%) 0.181
Vomit, n (%) 4 (13.33%) 2 (6.67%) 0.671
Chest pain, n (%) 2 (6.67%) 5 (16.67%) 0.424
Hemoptysis, n (%) 0 (0%) 3 (10.00%) 0.237
Positive PCR, n (%) 22 (73.33%) 30 (100.00%) > 0.9
Negative PCR, n (%) 8 (26.66%) 0 (00.00%)
WBC count (× 103/µl), mean (SD) 6.60 (3.65) 6.43 (3.69) 0.861
Lymphocyte (count/µl), mean (SD) 1082.68 (582.17) 1042.52 (590.81) 0.792
HB (g/dl), mean (SD) 13.35 (2.29) 12.65 (2.06) 0.218
PLT (× 103/µl), mean (SD) 194.20 (83.75) 203.30 (74.64) 0.658
AST (u/l), mean (SD) 35.93 (15.92) 33.93 (13.96) 0.607
ALT (u/l), mean (SD) 31.73 (8.57) 34.43 (9.69) 0.258
LDH (u/l), mean (SD) 619.20 (212.10) 599.67 (197.93) 0.714
CRP (mg/dl), mean (SD) 41.30 (28.86) 58.13 (52.80) 0.132
ESR (mm/hour), mean (SD) 60.00 (30.71) 66.03 (30.45) 0.448
Body temperature upon admission(°C), mean (SD) 37.03 (0.80) 37.93 (0.92) < 0.001
3rd day temperature (°C), mean (SD) 36.73 (0.36) 37.24 (0.69) 0.001
Body temperature at discharge (°C), mean (SD) 36.76 (0.47) 36.85 (0.46) 0.454
SPO2 upon admission (%), median (IQR) 86.0 (82.0–88.0) 87.5 (85.0–88.0) 0.148
3rd day SPO2 (%), median (IQR) 90.5 (88.0–92.0) 88.0 (80.0–91.0) 0.014
SPO2 at discharge (%), median (IQR) 93.5 (91.0–95.0) 92.5 (92.0–94.0) 0.406
ICU length of stay (day), median (IQR) 5.50 (5.0–10.0) 5.0 (5.0–7.0) 0.381
Hospital length of stay (day), median (IQR) 8.50 (7.0–12.0) 6.50(4.0–12.0) 0.028
Expire, n (%) 3 (10.00%) 3 (10.00%) > 0.9
Intubation, n (%) 5 (16.67%) 4 (13.33%) > 0.9
Corticosteroid treatment, n (%) 8 (26.66%) 7 (23.33%) 0.77
Severity score, mean (/10) (SD) 3.57 (1.357) 3.40 (1.476) 0.651
  1. SD standard deviation, n count, IQR interquartile range (25–75%), COPD chronic obstructive pulmonary disease, WBC white blood cell, HB hemoglobin, PLT platelet, AST aspartate transaminase, ALT alanine transaminase, LDH lactate dehydrogenase, CRP C-reactive protein, ESR erythrocyte sedimentation rate, SPO2 oxygen saturation, ICU intensive care unit, PCR polymerase chain reaction
\